This review summarises and discusses the 5-year outcomes from the randomised, open-label phase II
BRF113220 trial that were presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Chicago, USA (2017).
Independent expert commentary provided by Dr Andrew Haydon, a full time Medical Oncologist
at the Alfred Hospital in Melbourne.
Please login below to download this issue (PDF)